Selected research
Industry Research
Hospital Acquired Pneumonia Drugs Industry Research Report 2026
Market perspective
The global Hospital Acquired Pneumonia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hospital Acquired Pneumonia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hospital Acquired Pneumonia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hospital Acquired Pneumonia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hospital Acquired Pneumonia Drugs include Merck, GlaxoSmithKline, Bayer, AstraZeneca, Valneva, Meiji Holdings, Cubist Pharmaceutical, Basilea Pharmaceutica and Aridis Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hospital Acquired Pneumonia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hospital Acquired Pneumonia Drugs Market by Company
Merck
GlaxoSmithKline
Bayer
AstraZeneca
Valneva
Meiji Holdings
Cubist Pharmaceutical
Basilea Pharmaceutica
Aridis Pharmaceutical
Achaogen
Hospital Acquired Pneumonia Drugs Segment by Type
Phase II
Early Phase (Phase I & II)
Hospital Acquired Pneumonia Drugs Segment by Application
Hospital Pharmacies
Drug Store
Retail Pharmacies
E-Commerce
Hospital Acquired Pneumonia Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital Acquired Pneumonia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hospital Acquired Pneumonia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital Acquired Pneumonia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hospital Acquired Pneumonia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hospital Acquired Pneumonia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Phase II
- Early Phase (Phase I & II)
Applications
- Hospital Pharmacies
- Drug Store
- Retail Pharmacies
- E-Commerce
Companies covered
- Merck
- GlaxoSmithKline
- Bayer
- AstraZeneca
- Valneva
- Meiji Holdings
- Cubist Pharmaceutical
- Basilea Pharmaceutica
- Aridis Pharmaceutical
- Achaogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hospital Acquired Pneumonia Drugs Market Size (2021-2032)
- 2.2.2 Global Hospital Acquired Pneumonia Drugs Sales (2021-2032)
- 2.2.3 Global Hospital Acquired Pneumonia Drugs Market Average Price (2021-2032)
- 2.3 Hospital Acquired Pneumonia Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Phase II
- 2.3.3 Early Phase (Phase I & II)
- 2.4 Hospital Acquired Pneumonia Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Drug Store
- 2.4.4 Retail Pharmacies
- 2.4.5 E-Commerce
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hospital Acquired Pneumonia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hospital Acquired Pneumonia Drugs Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Hospital Acquired Pneumonia Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Hospital Acquired Pneumonia Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Hospital Acquired Pneumonia Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hospital Acquired Pneumonia Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hospital Acquired Pneumonia Drugs, Product Type & Application
- 3.8 Global Manufacturers of Hospital Acquired Pneumonia Drugs, Established Date
- 3.9 Global Hospital Acquired Pneumonia Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 Valneva
- 4.5.1 Valneva Company Information
- 4.5.2 Valneva Business Overview
- 4.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Valneva Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.5.5 Valneva Recent Developments
- 4.6 Meiji Holdings
- 4.6.1 Meiji Holdings Company Information
- 4.6.2 Meiji Holdings Business Overview
- 4.6.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.6.5 Meiji Holdings Recent Developments
- 4.7 Cubist Pharmaceutical
- 4.7.1 Cubist Pharmaceutical Company Information
- 4.7.2 Cubist Pharmaceutical Business Overview
- 4.7.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.7.5 Cubist Pharmaceutical Recent Developments
- 4.8 Basilea Pharmaceutica
- 4.8.1 Basilea Pharmaceutica Company Information
- 4.8.2 Basilea Pharmaceutica Business Overview
- 4.8.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.8.5 Basilea Pharmaceutica Recent Developments
- 4.9 Aridis Pharmaceutical
- 4.9.1 Aridis Pharmaceutical Company Information
- 4.9.2 Aridis Pharmaceutical Business Overview
- 4.9.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.9.5 Aridis Pharmaceutical Recent Developments
- 4.10 Achaogen
- 4.10.1 Achaogen Company Information
- 4.10.2 Achaogen Business Overview
- 4.10.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Achaogen Hospital Acquired Pneumonia Drugs Product Portfolio
- 4.10.5 Achaogen Recent Developments
5 Global Hospital Acquired Pneumonia Drugs Market Scenario by Region
- 5.1 Global Hospital Acquired Pneumonia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2021-2032
- 5.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2021-2026
- 5.2.2 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2027-2032
- 5.3 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2027-2032
- 5.4 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
- 5.4.1 North America Hospital Acquired Pneumonia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 5.4.3 North America Hospital Acquired Pneumonia Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
- 5.5.1 Europe Hospital Acquired Pneumonia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hospital Acquired Pneumonia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
- 5.7.1 South America Hospital Acquired Pneumonia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 5.7.3 South America Hospital Acquired Pneumonia Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2021-2032)
- 6.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Hospital Acquired Pneumonia Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2021-2032)
- 7.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Hospital Acquired Pneumonia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hospital Acquired Pneumonia Drugs Value Chain Analysis
- 8.1.1 Hospital Acquired Pneumonia Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hospital Acquired Pneumonia Drugs Production Mode & Process
- 8.2 Hospital Acquired Pneumonia Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hospital Acquired Pneumonia Drugs Distributors
- 8.2.3 Hospital Acquired Pneumonia Drugs Customers
9 Global Hospital Acquired Pneumonia Drugs Analyzing Market Dynamics
- 9.1 Hospital Acquired Pneumonia Drugs Industry Trends
- 9.2 Hospital Acquired Pneumonia Drugs Industry Drivers
- 9.3 Hospital Acquired Pneumonia Drugs Industry Opportunities and Challenges
- 9.4 Hospital Acquired Pneumonia Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst